Articles by George Koroneos - Pharmaceutical Executive

ADVERTISEMENT

Articles by George Koroneos

George Koroneos


Articles
Actos Deemed as Safe as Avandia
August 25, 2010

Results from a new study reveal that patients taking Takeda's diabetes treatment Actos have the same rate and kind of side effects as GSK's embattled Avandia. Is this a good sign?

Lilly Kills Two Alzheimer's Trials
August 18, 2010

In a huge blow to Eli Lilly's Alzheimer's pipeline, the drug giant was forced to end two clinical trials due to the fact that the treatment was actually making patients' memory recall worse.

Amgen Head and Neck Cancer Study: A Disappointment
August 11, 2010

Head-and-neck cancer treatment trial flops in Phase 3 trials causing Amgen stock to drop. The first-line therapy failed first and secondary goals compared with chemotherapy alone.

NicOx Shutters HQ After Approval Fail
August 4, 2010

In the wake of FDA's refusal to approve the lead drug in NicOx's pipeline, the French firm has decided to close its US headquarters.

5 Years Later: Conatus Acquires Idun
August 2, 2010

Former Idun Pharma team buys back company from Pfizer.

Adherence Through Education
August 1, 2010

Pharma's quest for patient adherence has been trying. Could better patient education be the answer?

Pfizer Suspends More Tanezunab Trials
July 20, 2010

Just weeks after ending tanezunab clinical studies in osteoarthritis patients, the drug giant is ceasing additional trials for two other indications.

FDA Prepares to Walk the Opiate REMS Line
June 30, 2010

FDA's meeting on the adoption of REMS for certain prescription opioids doesn't begin until July 22, but the agency's proposal released Tuesday portends a meeting fraught with conflict over the balance between curbing abuse and protecting patient access.

Mixed Criticism on Avandia Effectiveness
June 30, 2010

GSK's blockbuster diabetes drug Avandia was the subject of a number of studies this week offering good and bad news. But the company's big challenge is going to be FDA's advisory review panel set to meet in two short weeks.

ADVERTISEMENT

Click here